Hera-MI has developed Breast-SlimView, a patented clinical decision support system for 2D/3D mammography. Breast-SlimView offers an innovative and disruptive reading support where only relevant information is displayed. Radiologists will be able to free themselves from overloaded information and visualize potentially suspicious areas at a glance.
The technical process of the patent is called “negativation” (masking of healthy areas of the breast). Indeed, Breast-SlimView’s algorithm automatically detects and removes all normal physiological areas (vessels, glandular tissue, fatty tissue and mammary gland) and replaces them by artificial fat.
Artificial Intelligence will enable radiologists to decrease the time they spend on non-problematic cases and spend extra time on more complicated ones. Hera-MI helps radiologists to focus on their core business, which is their added value, the analysis of potentially suspicious areas.
Breast-SlimView was thought by a radiologist, for radiologists.
In order to offer technological and innovative solutions for breast cancer early detection, Hera-MI wishes to use automated learning techniques and images processing. These solutions improve the diagnosis quality and accuracy while decreasing radiologists’ interpretation time.
Hera-MI’ solutions will optimize breast cancer screening program accessibility. Patients will be treated more quickly which will offer them more chances to be cured from breast cancer.
Based on a technological innovation, Breast-SlimView includes several innovative features:
In the future, Hera-MI plans to develop and adjust Breast-SlimView to be used for other types of cancer such as lung cancer, prostate cancer and colorectal cancer.
Hera-MI received the CE mark approval for its software. Hera-MI began the installations in February 2020. Being CE Medical Device certified, Breast-SlimView can be sold in Europe, North Africa and Middle East without any extra regulatory adaption work.
In addition, Hera-MI submitted its FDA certification file beginning of the year and expects to be FDA cleared by September 2021. Upon certification receipt, Hera-MI will begin selling Breast-SlimView in the U.S market.
Hera-MI’s goal is to quickly implement an export development strategy in Europe, the USA and Middle East.